Enliven Therapeutics shares owned by Jpmorgan Chase & Co
Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Jpmorgan Chase & Co
from 13F filings
Historical chart of Jpmorgan Chase & Co investment in Enliven Therapeutics
Tip: Access up to 7 years of quarterly data
All positions including Enliven Therapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Quarterly reported holdings in Enliven Therapeutics by Jpmorgan Chase & Co
| Quarter filed | Position value | Share count | Share price at filing |
|---|---|---|---|
| 2025-09-30 | $508k | 25k | 20.47 |
| 2025-03-31 | $428k | 22k | 19.68 |
| 2024-12-31 | $444k | 20k | 22.50 |
| 2024-09-30 | $531k | 21k | 25.54 |
| 2024-06-30 | $486k | 21k | 23.37 |
| 2024-03-31 | $323k | 18k | 17.59 |
| 2023-12-31 | $332k | 24k | 13.84 |
| 2023-09-30 | $362k | 27k | 13.66 |
| 2023-06-30 | $626k | 31k | 20.41 |
| 2023-03-31 | $2.0k | 94 | 21.28 |